Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15331059 | 0.86 | SMN1; SMN2 (0.66) | SMN1; SMN2HTTKDM4EUSP2ALOX15 | |
| SCHEMBL23794464 | 0.84 | KDM4E (0.73) | SMN1; SMN2HTTKDM4EUSP2ALOX15 | |
| SCHEMBL209674 | 0.83 | KDM4E (0.71) | SMN1; SMN2HTTKDM4EUSP2ALOX15 | |
| SCHEMBL207842 | 0.82 | KDM4E (0.73) | SMN1; SMN2HTTKDM4EUSP2ALOX15 | |
| SCHEMBL15332590 | 0.78 | KDM4E (0.67) | SMN1; SMN2HTTKDM4EUSP2ALOX15 | |
| SCHEMBL10282872 | 0.77 | SMN1; SMN2 (0.60) | SMN1; SMN2KDM4EALDH1A1KMT2ARAB9A | |
| SCHEMBL209299 | 0.76 | KDM4E (0.61) | SMN1; SMN2HTTKDM4EUSP2ALOX15 | |
| SCHEMBL10282859 | 0.76 | LMNA (0.62) | ALDH1A1KMT2A | |
| SCHEMBL15329922 | 0.75 | KDM4E (0.60) | SMN1; SMN2HTTKDM4EUSP2ALOX15 | |
| SCHEMBL20805209 | 0.74 | SMN1; SMN2 (0.61) | SMN1; SMN2KDM4EUSP2ALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | HAVCR2, ZC3HAV1, MAVS | SMN1; SMN2 4526/4885HTT 3258/4885KDM4E 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.